Commentary & Deal Flow

Grifols SA (GRFSM) announced in a press release that it is actively pursuing the raising of sr sec notes, the proceeds of which will be used to refinance its EUR1bn 3.20% sr notes due 05/01/25 (callable at 100). Biz: a global healthcare company and industry leader in the production of plasma-derived medicines and transfusion medicine. HQ: Barcelona, Spain.

Grifols also said it is advancing towards the completion of the divestiture of a 20% interest in SRAAS to Haier Group for US$1.8bn, as part of its strategic partnership. Closing is expected in H1 2024, as planned. The proceeds from this divestment will be allocated to reduce secured debt obligations.